Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Digital patient modeling identifies predictive biomarkers of regorafenib response in elderly metastatic colorectal cancer

  • García Illarramendi, Juan Manuel|||0000-0003-3368-814X
  • Matos-Filipe, Pedro|||0000-0003-0492-0683
  • Mas, Jose Manuel
  • Farrés, Judith
  • Daura i Ribera, Xavier|||0000-0001-9235-6730
In silico clinical trials that simulate individualized mechanisms of action offer a powerful approach to assess drug efficacy across large and diverse patient populations, while also enabling the identification of predictive biomarkers. In this study, we conducted an in silico clinical trial of first-line, single-agent regorafenib in 399 elderly patients with metastatic colorectal cancer (mCRC). Individualized network-based models were constructed using patient-specific differential transcriptomic profiles and employed to simulate the target-specific effects of regorafenib. From this analysis, we identified both predictive and mechanistic biomarkers of treatment response. Notably, four proteins-MARK3, RBCK1, LHCGR, and HSF1-emerged as dual biomarkers, showing associations with both response mechanisms and predictive potential. Three of these (MARK3, RBCK1, and HSF1) were validated in an independent cohort of mCRC patients and were also found to be targets of previously reported regorafenib-predictive miRNAs. This study demonstrates a novel systems biology strategy for evaluating drug response in silico, leveraging transcriptomic data to simulate individual treatment outcomes and uncover clinically relevant biomarkers. Our findings suggest that such approaches may serve as valuable complements to traditional clinical trials for assessing drug efficacy and guiding precision oncology.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A decision support system based on artificial intelligence and systems biology for the simulation of pancreatic cancer patient status

  • Junet, Valentin
  • Matos Filipe, Pedro
  • García-Illarramendi, Juan Manuel
  • Ramírez, Esther
  • Oliva Miguel, Baldomero
  • Farrés, Judith
  • Daura, Xavier
  • Mas, José Manuel
  • Morales-Barrera, Rafael
Oncology treatments require continuous individual adjustment based on the measurement of multiple clinical parameters. Prediction tools exploiting the patterns present in the clinical data could be used to assist decision making and ease the burden associated to the interpretation of all these parameters. The goal of this study was to predict the evolution of patients with pancreatic cancer at their next visit using information routinely recorded in health records, providing a decision-support system for clinicians. We selected hematological variables as the visit's clinical outcomes, under the assumption that they can be predictive of the evolution of the patient. Multivariate models based on regression trees were generated to predict next-visit values for each of the clinical outcomes selected, based on the longitudinal clinical data as well as on molecular data sets streaming from in silico simulations of individual patient status at each visit. The models predict, with a mean prediction score (balanced accuracy) of 0.79, the evolution trends of eosinophils, leukocytes, monocytes, and platelets. Time span between visits and neutropenia were among the most common factors contributing to the predicted evolution. The inclusion of molecular variables from the systems-biology in silico simulations provided a molecular background for the observed variations in the selected outcome variables, mostly in relation to the regulation of hematopoiesis. In spite of its limitations, this study serves as a proof of concept for the application of next-visit prediction tools in real-world settings, even when available data sets are small., V.J. is part of a project (COSMIC) that has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 765158. P.M.F. receives funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 860303. J.M.G.I. receives funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 859962.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Mechanical strain stimulates COPII‐dependent secretory trafficking via Rac1

  • Phuyal, Santosh
  • Djaerff, Elena
  • Le Roux, Anabel-Lise
  • Baker, Martin J.
  • Fankhauser, Daniela
  • Mahdizadeh, Sayyed Jalil
  • Reiterer, Veronika
  • Parizadeh, Amirabbas
  • Felder, Edward
  • Kahlhofer, Jennifer C.
  • Teis, David
  • Kazanietz, Marcelo G.
  • Geley, Stephan
  • Eriksson, Leif A.
  • Roca-Cusachs Soulere, Pere
  • Farhan, Hesso
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Mechanical strain stimulates COPII‐dependent secretory trafficking via Rac1

  • Phuyal, Santosh
  • Djaerff, Elena
  • Le Roux, Anabel-Lise
  • Baker, Martin J.
  • Fankhauser, Daniela
  • Mahdizadeh, Sayyed Jalil
  • Reiterer, Veronika
  • Parizadeh, Amirabbas
  • Felder, Edward
  • Kahlhofer, Jennifer C.
  • Teis, David
  • Kazanietz, Marcelo G.
  • Geley, Stephan
  • Eriksson, Leif A.
  • Roca-Cusachs Soulere, Pere
  • Farhan, Hesso
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A decision support system based on artificial intelligence and systems biology for the simulation of pancreatic cancer patient status

  • Junet, Valentin
  • Matos Filipe, Pedro
  • García-Illarramendi, Juan Manuel
  • Ramírez, Esther
  • Oliva Miguel, Baldomero
  • Farrés, Judith
  • Daura, Xavier
  • Mas, José Manuel
  • Morales-Barrera, Rafael
Oncology treatments require continuous individual adjustment based on the measurement of multiple clinical parameters. Prediction tools exploiting the patterns present in the clinical data could be used to assist decision making and ease the burden associated to the interpretation of all these parameters. The goal of this study was to predict the evolution of patients with pancreatic cancer at their next visit using information routinely recorded in health records, providing a decision-support system for clinicians. We selected hematological variables as the visit's clinical outcomes, under the assumption that they can be predictive of the evolution of the patient. Multivariate models based on regression trees were generated to predict next-visit values for each of the clinical outcomes selected, based on the longitudinal clinical data as well as on molecular data sets streaming from in silico simulations of individual patient status at each visit. The models predict, with a mean prediction score (balanced accuracy) of 0.79, the evolution trends of eosinophils, leukocytes, monocytes, and platelets. Time span between visits and neutropenia were among the most common factors contributing to the predicted evolution. The inclusion of molecular variables from the systems-biology in silico simulations provided a molecular background for the observed variations in the selected outcome variables, mostly in relation to the regulation of hematopoiesis. In spite of its limitations, this study serves as a proof of concept for the application of next-visit prediction tools in real-world settings, even when available data sets are small., V.J. is part of a project (COSMIC) that has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 765158. P.M.F. receives funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 860303. J.M.G.I. receives funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 859962.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A decision support system based on artificial intelligence and systems biology for the simulation of pancreatic cancer patient status

  • Junet, Valentin|||0000-0002-6138-0612
  • Matos-Filipe, Pedro|||0000-0003-0492-0683
  • García Illarramendi, Juan Manuel|||0000-0003-3368-814X
  • Ramírez, Esther
  • Oliva Miguel, Baldomero|||0000-0003-0702-0250
  • Farrés, Judith
  • Daura i Ribera, Xavier|||0000-0001-9235-6730
  • Mas, José Manuel
  • Morales, Rafael
Oncology treatments require continuous individual adjustment based on the measurement of multiple clinical parameters. Prediction tools exploiting the patterns present in the clinical data could be used to assist decision making and ease the burden associated to the interpretation of all these parameters. The goal of this study was to predict the evolution of patients with pancreatic cancer at their next visit using information routinely recorded in health records, providing a decision-support system for clinicians. We selected hematological variables as the visit's clinical outcomes, under the assumption that they can be predictive of the evolution of the patient. Multivariate models based on regression trees were generated to predict next-visit values for each of the clinical outcomes selected, based on the longitudinal clinical data as well as on molecular data sets streaming from in silico simulations of individual patient status at each visit. The models predict, with a mean prediction score (balanced accuracy) of 0.79, the evolution trends of eosinophils, leukocytes, monocytes, and platelets. Time span between visits and neutropenia were among the most common factors contributing to the predicted evolution. The inclusion of molecular variables from the systems-biology in silico simulations provided a molecular background for the observed variations in the selected outcome variables, mostly in relation to the regulation of hematopoiesis. In spite of its limitations, this study serves as a proof of concept for the application of next-visit prediction tools in real-world settings, even when available data sets are small.